NDAORALTABLET
Approved
Apr 2008
Lifecycle
Post-LOE
Competitive Pressure
35/100
Clinical Trials
20
Data completeness
6/8 — Strong
TREXIMET (sumatriptan succinate and naproxen sodium) by Currax Pharmaceuticals is naproxen. Approved for cluster headache, migraine attacks. First approved in 2008.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TREXIMET is an oral fixed-dose combination of sumatriptan (a 5-HT1B/1D receptor agonist) and naproxen sodium (an NSAID) approved in 2008 for acute treatment of migraine attacks and cluster headaches. The dual mechanism provides cranial vasoconstriction and anti-inflammatory effects through serotonin receptor agonism and prostaglandin inhibition. The combination targets both vascular and inflammatory pathways in migraine pathophysiology.
$0.001BPart D
LOE ApproachingDeclining
Post-LOEProduct approaching loss of exclusivity with minimal Part D spend ($1M in 2023, 556 claims), signaling a contracting team and transition from growth to defensive positioning.
Mechanism of Action
naproxen. Sumatriptan binds with high affinity to cloned 5-HT 1B / 1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system,…
Indications (2)
Worked on TREXIMET at Currax Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.